Should I Buy ICU? ICU 2026 Analysis

Should You Buy SeaStar Medical Holding Corp (ICU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.480

1 Day change

2.90%

52 Week Range

25.700

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the longer-term trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no near-term catalysts.
Short-term momentum has improved (positive, expanding MACD), but the setup looks more like a tactical bounce than a durable trend reversal.
With price near the pivot (2.486) and close overhead resistance (2.654), upside appears capped unless volume/price breaks and holds above R1.
Intellectia Proprietary Trading Signals are not supportive today (no AI Stock Picker, no SwingMax), which reduces conviction for an impatient entry.

Technical Analysis

Trend: Bearish structure on moving averages (SMA_200 > SMA_20 > SMA_5), suggesting the broader trend is still down despite a recent bounce.
Momentum: MACD histogram at 0.0435 and positively expanding = bullish short-term momentum.
RSI(6): 59.67 (neutral-to-slightly-bullish), not overbought; room to move but not a strong “oversold rebound” signal either.
Key levels: Pivot 2.486 (current price ~2.538 slightly above pivot). Resistance at R1 2.654 then R2 2.757; support at S1 2.317 then S2 2.214.
Pattern-based forward odds: model suggests a positive skew in the next day/week (+6.85% / +13.53%) but a notably negative 1-month expectation (-24.02%), aligning with the bearish higher-timeframe MA structure.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Positive Catalysts

- Short-term technical momentum is improving (MACD turning/expanding positive), which can support a near-term bounce.
- Revenue growth is strong YoY in the latest reported quarter (though from a small base).

Neutral/Negative Catalysts

- No news in the last week: no clear event-driven catalyst to justify chasing strength.
- Broader technical trend remains bearish (MA stack), increasing risk that rallies fade into resistance.
- Pattern-based outlook flags elevated downside risk over the next month (-24.02% expected move in the provided model).
- Trading trends: Hedge funds neutral and insiders neutral, providing no “smart money” confirmation.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 183,000, up +169.12% YoY (rapid growth, but still very small absolute revenue).
Net income: -3.472M, down -22.47% YoY (losses widened vs prior year period).
EPS: -1.32, down -87.96% YoY (deterioration).
Gross margin: 92.35%, down -7.65% YoY (still high, but trending lower).
Takeaway: top-line is accelerating, but profitability metrics worsened materially—growth is not yet translating into earnings improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so there is no clear read on recent Wall Street upgrades/downgrades or target revisions.
Practical pro view (if constructive): strong YoY revenue growth and high gross margin profile could support a long-term thesis.
Practical con view (if cautious): worsening net income/EPS trend and lack of near-term catalysts/coverage typically keep sentiment fragile and price action headline-sensitive.

Politicians/Congress:

No recent congress trading data available in the last 90 days.

1 Analyst Rating

Wall Street analysts forecast ICU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1 USD with a low forecast of 1 USD and a high forecast of 1 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.410

Low

Averages

High